It's Time For-Charitable Organization-Cincinnati-Removing T1 D Damage
Video Credit List is stored here http://broadcaster.beazil.net/public/credits/youtube/videos/42340 JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities; collaborating regionally for efficiency and broader fundraising impact; and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers in more than 100 locations throughout the United States and our 6 international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. Type 1 Diabetes can occur at any age, but most commonly is diagnosed from infancy to the late 30s. Type 1 diabetes happens when your immune system destroys cells in your pancreas called beta cells. They’re the ones that make insulin. What Treatments are Used for Type 1 Diabetes?
The two goals of diabetes treatment are to make sure you feel well day-to-day and to prevent or delay long-term health problems. The best way to reach those goals is by:
– taking insulin
– planning your meals—choosing what, how much, and when to eat
– being physically active
You want a cure. So does JDRF. And we are committed to funding the development of new therapies and treatments to keep people with T1D healthier, longer, until that cure is found. That’s why we invest in multiple therapeutic approaches to cure, prevent and treat T1D. We identify and invest in promising therapies in their early stages, helping researchers pursue innovative ideas and approaches. Cincinnati is a city in the U.S. state of Ohio that serves as county seat of Hamilton County. Settled in 1788, the city is located on the north side of the confluence of the Licking with the Ohio River. The latter forms the border between the states of Ohio and Kentucky. Cincinnati is the third-largest city in Ohio and the 65th-largest city in the United States with a population of 298,165 people (2014), making it the 28th-largest Metropolitan Statistical Area (MSA) in the United States and the largest centered in Ohio. The city is also part of the larger Cincinnati–Middletown–Wilmington Combined Statistical Area (CSA), which had a population of 2,172,191 in the 2010 census. The Health Care and Social Assistance industry includes establishments and services such as:
hospitals, nursing and residential care facilities and out-patient care centres; offices of health practitioners (i.e. dentists, doctors, optometrists and chiropractors); medical and diagnostic laboratories; home health care services; ambulance services; social assistance services (i.e. for children, youth, the elderly, families); community food, housing, emergency and relief services; vocational rehabilitation services; and daycare services JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF has led the search for a cure for T1D since our founding in 1970. In those days, people commonly called the disease “juvenile diabetes” because it was frequently diagnosed in, and strongly associated with, young children. Our organization began as the Juvenile Diabetes Foundation. Later, to emphasize exactly how we planned to end the disease, we added a word and became the Juvenile Diabetes Research Foundation.Today, we know an equal number of children and adults are diagnosed every day—approximately 110 people per day.
The important points are:
Traveling with Diabetes,speak out,2-h plasma glucose value,DILfrequency study,GMP,preventive therapy research,funding,The Blue Chip City,sugar diabetes,Insulin injections,Encapsulation,Blood Glucose,MultiPepT1De,“All-Star” charity,fasting plasma glucose value,undiagnosed type 2 diabetes,Juvenile Diabetes Research Foundation,care delivery systems,Countdown,ketosis,Medtronic Minimed Insulin Pump Users,biguanide,fundraising,ketonuria,FPG value,Pathaway to Prevention,Heart Disease,Technosphere insulin-inhalation system,therapeutic strategies,Microvascular Complications,preventive therapies,insulin analogues,Mary Tyler Moore,blood glucose level,heart attack,CO,plasma glucose criteria,latent autoimmune diabetes in adults,DKA,no insulin production,gestational diabetes,tolbutamide,50/50 insulin,OGTT,Clinicians,mean glucose,Blood Glucose Level,blindness,Oral Glucose Tolerance Test,Aaron Kowalski,secondary diabetes,DPP-4 inhibitors,diabetogenic,EsTiD,Lantus,diabetes management,The Yankee.